REAX vs. NVO
REAX (Real Brokerage Inc) and NVO (Novo Nordisk A/S) are both stocks. REAX operates in Real Estate - Services (Real Estate), while NVO operates in Biotechnology (Healthcare). Over the past 3 years, REAX returned 8.23%/yr vs -16.72%/yr for NVO. At a 0.13 correlation, their price movements are largely independent.
Performance
REAX vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, REAX achieves a -55.89% return, which is significantly lower than NVO's -14.57% return.
REAX
- 1D
- -6.40%
- 1M
- -22.22%
- YTD
- -55.89%
- 6M
- -58.72%
- 1Y
- -63.49%
- 3Y*
- 8.23%
- 5Y*
- —
- 10Y*
- —
NVO
- 1D
- -2.14%
- 1M
- -5.38%
- YTD
- -14.57%
- 6M
- -8.62%
- 1Y
- -38.01%
- 3Y*
- -16.72%
- 5Y*
- 2.89%
- 10Y*
- 6.21%
REAX vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
REAX Real Brokerage Inc | -55.89% | -20.65% | 187.50% | 52.38% | -71.54% | -63.10% |
NVO Novo Nordisk A/S | -14.57% | -39.22% | -15.93% | 54.84% | 22.66% | 33.16% |
Correlation
The correlation between REAX and NVO is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since Jun 16, 2021 | 0.13 |
Fundamentals
REAX:
$360.14M
NVO:
$186.85B
REAX:
-$0.03
NVO:
$27.42
REAX:
0.17
NVO:
0.57
REAX:
5.48
NVO:
0.92
REAX:
$2.08B
NVO:
$327.80B
REAX:
$173.33M
NVO:
$268.30B
REAX:
-$4.17M
NVO:
$181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
REAX vs. NVO — Risk / Return Rank
REAX
NVO
REAX vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Real Brokerage Inc (REAX) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| REAX | NVO | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -1.11 | -0.74 | -0.38 |
Sortino ratioReturn per unit of downside risk | -1.88 | -0.83 | -1.04 |
Omega ratioGain probability vs. loss probability | 0.78 | 0.88 | -0.10 |
Calmar ratioReturn relative to maximum drawdown | -0.91 | -0.69 | -0.22 |
Martin ratioReturn relative to average drawdown | -1.73 | -1.03 | -0.70 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| REAX | NVO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -1.11 | -0.74 | -0.38 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.08 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.19 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.43 | 0.47 | -0.90 |
Drawdowns
REAX vs. NVO - Drawdown Comparison
The maximum REAX drawdown since its inception was -89.60%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for REAX and NVO.
Loading charts...
Drawdown Indicators
| REAX | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.60% | -74.70% | -14.90% |
Max Drawdown (1Y)Largest decline over 1 year | -70.07% | -55.03% | -15.04% |
Max Drawdown (3Y)Largest decline over 3 years | -75.83% | -74.70% | -1.13% |
Max Drawdown (5Y)Largest decline over 5 years | — | -74.70% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -74.70% | — |
Current DrawdownCurrent decline from peak | -83.90% | -69.48% | -14.42% |
Average DrawdownAverage peak-to-trough decline | -69.33% | -17.76% | -51.57% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 36.77% | 36.88% | -0.11% |
Volatility
REAX vs. NVO - Volatility Comparison
Real Brokerage Inc (REAX) has a higher volatility of 19.02% compared to Novo Nordisk A/S (NVO) at 7.84%. This indicates that REAX's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| REAX | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.02% | 7.84% | +11.18% |
Volatility (6M)Calculated over the trailing 6-month period | 48.52% | 37.83% | +10.69% |
Volatility (1Y)Calculated over the trailing 1-year period | 57.32% | 51.76% | +5.56% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 71.26% | 38.21% | +33.05% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 71.26% | 32.49% | +38.77% |
Dividends
REAX vs. NVO - Dividend Comparison
REAX has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.29%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 4.29% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
REAX Real Brokerage Inc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
REAX vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Real Brokerage Inc and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
REAX vs. NVO - Profitability Comparison
REAX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Real Brokerage Inc reported a gross profit of 41.58M and revenue of 465.55M. Therefore, the gross margin over that period was 8.9%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
REAX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Real Brokerage Inc reported an operating income of -3.13M and revenue of 465.55M, resulting in an operating margin of -0.7%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
REAX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Real Brokerage Inc reported a net income of -3.42M and revenue of 465.55M, resulting in a net margin of -0.7%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
Frequently Asked Questions
REAX and NVO have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
REAX has higher volatility (19.02%) compared to NVO (7.84%). In terms of maximum drawdown, REAX dropped -89.60% vs NVO's -74.70%.
NVO currently has the higher Sharpe Ratio (-0.74 vs -1.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for REAX and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer